Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia

Journal of Clinical Investigation

Volumn 113, Issue 9, 2004, Pages 1353-1363

  Talbot, Konrad ^a   Eidem, Wess L ^a   Tinsley, Caroline L ^b   Benson, Matthew A ^b   Thompson, Edward W ^a   Smith, Rachel J ^a   Hahn, Chang Gyu ^a   Siegel, Steven J ^a   Trojanowski, John Q ^a   Gur, Raquel E ^a   Blake, Derek J ^b   Arnold, Steven E ^a,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; DYSBINDIN 1; DYSTROBREVIN; DYSTROBREVIN BINDING PROTEIN 1; GLUTAMATE TRANSPORTER; GLUTAMIC ACID; GLYCOPROTEIN; UNCLASSIFIED DRUG; VESICULAR GLUTAMATE TRANSPORTER 1; CARRIER PROTEIN; DTNBP1 PROTEIN, HUMAN; GLUTAMATE RECEPTOR;

AGED; ANIMAL CELL; ARTICLE; BRAIN; CHROMOSOME 6P; CINGULATE GYRUS; CLINICAL ARTICLE; COGNITIVE DEFECT; COMPLEX FORMATION; CONTROLLED STUDY; DENTATE GYRUS; FEMALE; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; MALE; NERVE ENDING; NONHUMAN; NUCLEOTIDE SEQUENCE; POSTSYNAPTIC MEMBRANE; PRESYNAPTIC NERVE; PRIORITY JOURNAL; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; SUBICULUM; ADULT; ANIMAL; BIOLOGICAL MODEL; CASE CONTROL STUDY; CELL STRAIN COS1; CERCOPITHECUS; COMPARATIVE STUDY; GENE EXPRESSION; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MIDDLE AGED; NERVE CELL; PATHOLOGY; SEX RATIO; SYNAPTOSOME; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; CARRIER PROTEINS; CASE-CONTROL STUDIES; CERCOPITHECUS AETHIOPS; COS CELLS; FEMALE; GENE EXPRESSION; GENETIC PREDISPOSITION TO DISEASE; HIPPOCAMPUS; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NEURONS; PENNSYLVANIA; PRESYNAPTIC TERMINALS; RECEPTORS, GLUTAMATE; SCHIZOPHRENIA; SEX RATIO;

EID: 2342512304     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200420425     Document Type: Article

References (75)

1. Owen, M.J., O'Donovan, M.C., and Gottesman, I.I. 2002. Schizophrenia. In Psychiatric genetics and genomics. P. McGuffin, M.J. Owen, and I.I. Gottesman, editors. Oxford University Press. New York, New York, USA. 247-266.
2. Goldner, E.M., Hsu, L., Waraich, P., and Somers, J.M. 2002. Prevalence and incidence studies of schizophrenic disorders: a systemacic review of the literacure. Can. J. Psychiatry. 47:833-843.
3. Riley, B.P., and McGuffin, P. 2000. Linkage and associated studies of schizophrenia. Am. J. Med. Genet. 97:23-44.
4. Sklar, P. 2002. Linkage analysis in psychiatric disorders: the emerging picture. Annu. Rev. Genomics Hum. Genet. 3:371-413.
5. Lewis, C.M., et al. 2003. Genome scan meta-analysis of schizophrenia and bipolar disorder, pare II: schizophrenia. Am. J. Hum. Genet. 73:34-48.
6. O'Donovan, M.C., Williams, N.M., and Owen, M.J. 2003. Recent advances in the genetics of schizophrenia. Hum. Mol. Genet. 12:R125-R133.
7. Owen, M.J., Williams, N.M., and O'Donovan, M.C. 2004. The molecular genetics of schizophrenia: new findings promise new insights. Mol. Psychiatry. 9:14-27.
8. Cloninger, C.R. 2002. The discovery of susceptibility genes for mental disorders. Proc. Natl. Acad. Sci. U. S. A. 99:13365-13367.
9. Harrison, P.J., and Owen, M.J. 2003. Genes for schizophrenia? Recent findings and their pathological implications. Lancet. 361:417-419.
10. Straub, R.E., et al. 2002. Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. Am. J. Hum. Genet. 71:337-348.
11. Datta, S.R., et al. 2003. Tests of linkage disequilibrium between schizophrenia and genetic markers at the G72 and dysbindin loci. Presentation at: XIth World Congress of Psychiatric Genetics. October 4-8. Quebec City, Quebec, Canada.
12. van den Oord, E.J.C.G., et al. 2003. Identification of a high-risk haplotype for the dystrobrevin binding protein 1 (DTNBP1) gene in the Irish study of high-density schizophrenia families. Mol. Psychiatry. 8:499-510.
13. Williams, N.M., et al. 2004. Identification in 2 independent samples of a novel schizophrenia risk haplotype of the dystrobrevin binding protein gene (DTNBP1). Arch. Gen. Psychiatry. 61:336-344.
14. Bakker, S.C., et al. 2003. Association study of the neuregulin, dysbindin and G72 genes in a large sample of Dutch schizophrenic patients. Am. J. Med. Genet. 122B:19. (Abstr.)
15. Schwab, S.G., et al. 2003. Support for association of schizophrenia with genetic variation in the 6p22.3 gene, dysbindin, in sib-pair families with linkage and in an additional sample of triad families. Am. J. Hum. Genet. 72:185-190.
16. Van Den Bogaert, A., et al. 2003. The DTNBP1 (dysbindin) gene contributes to schizophrenia, depending on family history of the disease. Am. J. Hum. Genet. 73:1438-1443.
17. Kirov, G., et al. 2004. Strong evidence for association between the dystrobrevin binding protein 1 gene (DTNBP1) and schizophrenia in 488 parent-offspring trios from Bulgaria. Biol. Psychiatry. In press.
18. Tang, J.X., et al. 2003. Family-based association study of DTNBP1 in 6p22.3 and schizophrenia. Mol. Psychiatry. 8:717-718.
19. Shi, Y.Y., et al. 2003. Non-family based association study of DTNBP1 in 6p22.3 and schizophrenia in geographically and genetically structured Chinese Han population. Am. J. Med. Genet. 122B:102. (Abstr.)
20. Yamada, K., et al. 2003. Suggestive evidence of association between the DTNBP1 gene and schizophrenia in the Japanese samples. Am. J. Med. Genet. 122B:131.
21. Morris, D.W., et al. 2003. No evidence for association of the dysbindin gene (DTNBP1) with schizophrenia in an Irish population-based study. Schizophr. Res. 60:167-172.
22. Maier, W., Zobel, A., and Rietschel, M. 2003. Genetics of schizophrenia and affective disorders. Pharmacopsychiatry. 36(Suppl. 3):5195-5202.
23. McClintock, B.W., et al. 2002. Reduced expression of the common dysbindin transcript in the dorsolateral cortex of schizophrenics. Presentation at: 41st Annual Meeting of the American College of Neuropsychopharmacology. December 8-12. San Juan, Puerto Rico, USA.
24. Straub, R.E., et al. 2004. Dysbindin protein is decreased in the dorsolateral prefrontal cortex of schizophrenia patients. Biol. Psychiatry. 55(Suppl. 1):116S. (Abstr.)
25. Benson, M.A., Newey, S.E., Martin-Rendon, E., Hawkes, R., and Blake, D.J. 2001. Dysbindin, a novel coiled-coil-containing protein that interacts with the dystrobrevins in muscle and brain. J. Biol. Chem. 276:24232-24241.
26. Li, W., et al. 2003. Hermansky-Pudlak syndrome type 7 (HPS-7) results from mutant dysbindin, a member of the biogenesis of lysosome-related organelles complex 1 (BLOC-1). Nat Genet. 35:84-89.
27. Blake, D.J., Weir, A., Newey, S.E., and Davies, K.E. 2002. Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol. Rev. 82:291-329.
28. Lidov, H.G.W. 1996. Dystrophin in the nervous system. Brain Pathol. 6:63-77.
29. Blake, D.J., Hawkes, R., Benson, M.A., and Beesley, P.W. 1999. Different dystrophin-like complexes are expressed in neurons and glia. J. Cell Biol. 147:645-657.
30. Blake, D.J., Nawrotzki, R., Loh, N.Y., Górecki, D.C., and Davies, K.E. 1998. β-Dystrobrevin, a member of the dystrophin-related protein family. Proc. Natl. Acad. Sci. U. S. A. 95:241-246.
31. Benes, F.M. 2000. Emerging principles of altered neural circuitry in schizophrenia. Brain Res. Rev. 31:251-269.
32. Mimics, K., Middleton, F.A., Lewis, D.A., and Levitt, P. 2001. Analysis of complex disorders with gene expression microarrays: schizophrenia as a disease of the synapse. Trends Neurosci. 24:479-486.
33. Bray, N.J., Buckland, P.R., Owen, M.J., and O'Donovan, M.C. 2003. Cis-acting variation in the expression of a high proportion of genes in human brain. Hum. Genet. 113:149-153.
34. Lederhendler, I., and Schulkin, J. 2000. Behavioral neuroscience: challenges for the era of molecular biology. Trends Neurosci. 23:451-454.
35. A receptors in mice lacking dystrophin (mdx mice). Eur. J. Neurosci. 11:4457-4462.
36. A receptors and gephyrin. J. Neurosci. 22:4805-4813.
37. Harrison, P.J., and Eastwood, S.L. 2001. Neuropathological studies of synaptic connectivity in the hippocampal formation in schizophrenia. Hippocampus. 11:508-519.
38. Dwork, A.J. 2002. Post mortem studies of the hippocampal formation in schizophrenia. In The postmortem brain in psychiatric research. G. Agam, I.P. Everall, and R.H. Belmaker, editors. Kluwer Academic Publishers. Boston, Massachusetts, USA, 253-266.
39. Schmajuk, N.A. 2001. Hippocampal dysfunction in schizophrenia. Hippocampus. 11:599-613.
40. Arnold, S.E., et al. 1995. Prospective clinicopathologic studies of schizophrenia; accrual and assessment of patients. Am. J. Psychiatry. 152:731-737.
41. Torrey, E.F., Webster, M., Knable, M., Johnston, N., and Yolken, R.H. 2000. The Stanley Foundation brain collection and neuropathology consortium. Schizophr. Res. 44:151-155.
42. Maddox, P.H., and Jenkins, D. 1987. 3-Aminopropyltriethoxysilane (APES): a new advance in section adhesion. J. Clin. Pathol. 40:1256-1260.
43. Kaneko, T., Fujiyama, F., and Hioki, H. 2002. Immunohistochemical localization of candidates for vesicular glutamate transporters in the rat brain. J. Comp. Neurol. 444:39-62.
44. Pileri, S.A., et al. 1997. Antigen retrieval techniques in immunohistochemistry: comparison of different methods. J. Pathol. 183:116-123.
45. Teclemariam-Mesbah, R., Wortel, J., Romijn, H.J., and Buijs, R.M. 1997. A simple silver-gold intensification procedure for double DAB labeling studies in electron microscopy. J. Histochem. Cytochem. 45:619-621.
46. Siegel, S.J., et al. 2002. Surgically implantable long-term antipsychotic delivery systems for the treatment of schizophrenia. Neuropsychopharmacology. 26:817-823.
47. Scharfman, H.E., Witter, M.P., and Schwarcz, R. 2000. The parahippocampal region: implications for neurological and psychiatric diseases. Introduction. Ann. N. Y. Acad. Sci. 911:ix-xiii.
48. Insausti, R., and Amaral, D.G. 2004. Hippocampal formation. In The human nervous system. 2nd edition. G. Paxinos and J. Mai, editors. Academic Press. New York, New York, USA. 871-914.
49. Witter, M.P., and Amaral, D.G. 2004. Hippocampal region. In The rat nervous system. 3rd edition. G. Paxinos, editor. Academic Press. New York, New York, USA.
50. Kapur, S., et al. 1997. The relationship between D2 receptor occupancy and plasma levels on low dose oral haloperidol: a PET study. Psychophamacology. 131:148-152.
51. Walker, M.A., et al. 2002. Estimated neuronal populations and volumes of the hippocampus and its subfields in schizophrenia. Am. J. Psychiatry. 159:821-828.
52. Gornick, M., et al. 2003. Polymorphisms in dysbindin (DTNBP1, 6p22.3) are associated with intermediate phenotypes measured by the Premorbid Adjustment Scale (PAS) in cases of childhood onset psychosis. 53rd Annual Meeting of the American Society of Human Genetics. November 4-8. Los Angeles, California, USA. (Abstr.)
53. Huard, J., Côté, P.-Y., Parent, A., Bouchard, J.-P., and Tremblay, J.P. 1992. Dystrophin-like immunoreactivity in monkey and human brain areas involved in learning and motor functions. Neurosci. Lett. 141:181-186.
54. Dawirs, R.R., Teuchert-Noodt, G., Hildebrandt, K., and Fei, F. 2000. Granule cell proliferation and axon terminal degradation in the dentate gyrus of gerbils (Meriones unguiculatus) during maturation, adulthood and aging. J. Neural Transm. 107:639-647.
55. Eastwood, S.L., et al. 1995. Decreased expression of mRNAs encoding non-NMDA glutamate receptors GluR1 and GluR2 in medial temporal lobe neurons in schizophrenia. Mol. Brain Res. 29:211-223.
56. Porter, R.H.P., Eastwood, S.L., and Harrison, P.J. 1997. Distribution of kainate receptor subunit mRNAs in human hippocampus, neocortex and cerebellum, and bilateral reduction of hippocampal GluR6 and KA2 transcripts in schizophrenia. Brain Res. 751:217-231.
57. Law, A.J., and Deakin, J.F.W. 2001. Asymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses. Neuroreport. 12:2971-2974.
58. Konradi, C., and Heckers, S. 2003. Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment. Pharmacol. Ther. 97:153-179.
59. Collier, D.A., and Li, T. 2003. The genetics of schizophrenia: glutamate not dopamine? Eur. J. Pharmacol. 480:177-184.
60. Moghaddam, B. 2003. Bringing order to the glutamate chaos in schizophrenia. Neuron. 40:881-884.
61. Sawa, A., and Snyder, S.H. 2003. Schizophrenia: neural mechanisms for novel therapies. Mol. Med. 9:3-9.
62. Hetherington, P.A., Austin, K.B., and Shapiro, M.L. 1994. Ipsilateral associational pathway in the dentate gyrus: an excitatory feedback system that supports N-methyl-D-aspartate-dependent long-term potentiation. Hippocampus. 4:422-438.
63. Jackson, M.B., and Scharfman, H.E. 1996. Positive feedback from hilar mossy cells to granule cells in the dentate gyrus revealed by voltage-sensitive dye and microelectrode recording. J. Neurophysiol. 76:601-616.
64. Wenzel, H.J., Buckmaster, P.S., Anderson, N.L., Wenzel, M.E., and Schwartzkroin, P.A. 1997. Ultrastructural localization of neurotransmitter immunoreactivity in mossy cell axons and their synaptic targets in the rat dentate gyrus. Hippocampus. 7:559-570.
65. Witter, M.P., Wouterlood, F.G., Naber, P.A., and van Haeften, T. 2000. Anatomical organization of the parahippocampal-hippocampal network. Ann. N. Y. Acad. Sci. 911:1-24.
66. Scharfman, H.E. 1991. Dentate hilar cells with dendrites in the molecular layer have lower thresholds for synaptic activation by perforant path than granule cells. J. Neurosci. 11:1660-1673.
67. Sik, A., Pentonnen, M., and Buzsáki, G. 1997. Interneurons in the hippocampal dentate gyrus: an in vivo intracellular study. Eur. J. Neurosci. 9:573-588.
68. Vizi, E.S., and Kiss, J.P. 1998. Neurochemistry and pharmacology of the major hippocampal transmitter systems: synaptic and nonsynaptic interactions. Hippocampus. 8:566-607.
69. Ishizuka, N., Weber, J., and Amaral, D.G. 1990. Organization of intrahippocampal projections originating from CA3 pyramidal cells in the rat. J. Comp. Neurol. 295:580-623.
70. Nakazawa, K., et al. 2002. Requirement for hippocampal CA3 NMDA receptors in associative memory recall. Science. 297:211-218.
71. 2+ accumulation and metabotropic glutamate receptor activation associated with an N-methyl-D-aspartate receptor-independent long-term potentiation in hippocampal CA1 neurons. Hippocampus. 4:546-558
72. Small, S.A. 2002. The longitudinal axis of the hippocampal formation: its anatomy, circuitry, and role in cognitive function. Rev. Neurosci. 13:183-194.
73. Lisman, J.E. 1999. Relating hippocampal circuitry to function: recall of memory sequences by reciprocal dentate-CA3 interactions. Neuron. 22:233-242.
74. Gur, R.C., Moelter, S.T., and Ragland, J.D. 2000. Learning and memory in schizophrenia. In Cognition in schizophrenia: impairments, importance, and treatment strategies. T. Sharma and P. Harvey, editors. Oxford University Press. New York, New York, USA. 73-91.
75. Goldberg, T.E., David, A., and Gold, J.M. 2003. Neurocognitive deficits in schizophrenia. In Schizophrenia. 2nd edition. S.R. Hirsch and D.R. Weinberger, editors. Blackwell Publishing. Maiden, Massachusetts, USA. 168-184.